Valneva and the Serum Institute of India (SII) have ended a license agreement for chikungunya vaccine supply in Asia after ...

In early December, the 2025 updates of China’s NRDL were finalised with a total of 114 drugs, including Western drugs and ...

The AMD market is expected to grow at a CAGR of 10.2% over the course of the forecast period (2024–34), reaching $20.5bn ...

Outlook Therapeutics has received the US FDA's CRL regarding the BLA resubmission for ONS-5010/LYTENAVA to treat wet AMD.

Emmaus Life Sciences has entered into a licensing and exclusive distribution agreement with NeoImmuneTech (NIT) for Endari, a ...

Genmab is discontinuing development of acasunlimab after a pipeline review, pivoting focus to other oncology antibodies.

Maryland’s Prescription Drug Affordability Board (PDAB) serves as a bellwether for how other states may address high drug ...

Johnson & Johnson (J&J) has completed its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, for ...

Data indicating unequal treatment effects in women has prompted calls for more nuance in Alzheimer’s diagnosis and drug ...

Sanofi has agreed to acquire hepatitis B vaccine manufacturer Dynavax for an equity value of around $2.2bn, bolstering the ...

Updated versions of best-selling drugs may mitigate some of the impact of patent cliff losses, but strategy is key in a ...